Highlights & Chart Patterns of Sun Pharma Advanced Resea
Strong price rise supported with good volume.
Spinning Top Continuation Heikin Ashi Pattern formed
Bullish Heikin Ashi Pattern formed with high volume
Short Term Lower High and Lower Lows , Top Points :181.45/23-Mar-23 00:00 220.75/13-Feb-23 00:00 , Bottom Points : 162.9/22-Mar-23 00:00 185.05/27-Feb-23 00:00 188.5/10-Feb-23 00:00
Short Term Lower High and Lower Lows , Top Points :181.45/23-Mar-23 00:00 193.25/03-Mar-23 00:00 206.35/16-Feb-23 00:00 , Bottom Points : 162.9/22-Mar-23 00:00 185.05/27-Feb-23 00:00 193.65/20-Feb-23 00:00
Short Term Lower High and Lower Lows , Top Points :181.45/23-Mar-23 00:00 193.5/01-Mar-23 00:00 220.75/13-Feb-23 00:00 , Bottom Points : 162.9/22-Mar-23 00:00 188.5/10-Feb-23 00:00
Macd /Signal line bullish crossover. Seems to be trending nicelyToo frequent crossovers
Share Price History of Sun Pharma Advanced Resea
Date
Open
High
Low
Close
Volume
28-Mar-23
168.95
184.90
163.25
178.90
7717 K
27-Mar-23
172.20
173.20
167.30
168.50
838 K
24-Mar-23
179.00
181.20
170.55
173.20
2316 K
23-Mar-23
163.55
186.30
163.55
181.45
14918 K
22-Mar-23
164.10
165.50
162.20
162.90
273 K
21-Mar-23
165.00
166.60
162.10
163.30
524 K
20-Mar-23
173.95
173.95
162.95
164.35
457 K
17-Mar-23
169.85
171.55
168.00
170.55
311 K
16-Mar-23
169.45
171.90
166.10
168.70
425 K
15-Mar-23
180.15
182.95
167.35
169.35
1711 K
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.
Steps To Customise this view
You can now customize Equity with technical , SMA , Fin Data, chart patterns in one Page. Click here to view guide
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick
TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential
TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.
